HDFC MF ו-ADIA מובילות עסקה חסומה בשווי 777 קרוור רופי ב-Corona Remedies
שינוי משמעותי במבנה האחזקות של חברת התרופות Corona Remedies Limited התרחש ב-17 ביוני 2026, באמצעות עסקה חסומה (block deal) משמעותית בבורסה. שחקנים מוסדי
Other international entities involved included the Aberdeen Standard Sicav I - Asian Smaller Companies Fund (Rs 47.4 crore), India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund (Rs 25.7 crore), and the TCW White Oak Emerging Markets Equity Fund, which made the smallest acquisition of 1,920 shares worth Rs 33 lakh. This mix of domestic giants and global sovereign/institutional wealth underscores the growing institutional interest in the company’s market position.
Key Takeaways
- Significant Divestment: Sepia Investments and Anchor Partners offloaded a combined stake worth approximately Rs 776.9 crore at a price of Rs 1,730 per share.
- HDFC MF Lead Buyer: HDFC Mutual Fund dominated the transaction, investing Rs 423.9 crore to acquire 24.5 lakh shares.
- Global Confidence: The deal saw participation from major international entities, including the Abu Dhabi Investment Authority and various Aberdeen-managed funds, signaling broad institutional trust.